You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Sulfur hexafluoride lipid-type a microspheres - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for sulfur hexafluoride lipid-type a microspheres and what is the scope of patent protection?

Sulfur hexafluoride lipid-type a microspheres is the generic ingredient in one branded drug marketed by Bracco and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sulfur hexafluoride lipid-type a microspheres has thirty-four patent family members in twelve countries.

One supplier is listed for this compound.

Summary for sulfur hexafluoride lipid-type a microspheres
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for sulfur hexafluoride lipid-type a microspheres
Generic Entry Date for sulfur hexafluoride lipid-type a microspheres*:
Constraining patent/regulatory exclusivity:
Dosage:
FOR SUSPENSION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sulfur hexafluoride lipid-type a microspheres

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bracco Diagnostics, IncPhase 3
Children's Hospital of PhiladelphiaPhase 3
Children's Mercy Hospital Kansas CityPhase 2

See all sulfur hexafluoride lipid-type a microspheres clinical trials

Pharmacology for sulfur hexafluoride lipid-type a microspheres

US Patents and Regulatory Information for sulfur hexafluoride lipid-type a microspheres

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for sulfur hexafluoride lipid-type a microspheres

Country Patent Number Title Estimated Expiration
Israel 288095 מוצר מיובש בהקפאה ותרחיף מיקרו-בועיות מלאי גז (Freeze-dried product and gas-filled microvesicles suspension) ⤷  Try a Trial
Singapore 11202111756U GAS-FILLED MICROVESICLES ⤷  Try a Trial
South Korea 20210029712 기체-충전 미세소포를 위한 동결-건조 제제 ⤷  Try a Trial
South Korea 102556398 ⤷  Try a Trial
Japan 7128299 ⤷  Try a Trial
Mexico 2020012604 FORMULACION CONGELADA PARA MICROVESICULAS LLENAS DE GAS. (FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES.) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for sulfur hexafluoride lipid-type a microspheres

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1556389 16C0004 France ⤷  Try a Trial PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
1556389 92943 Luxembourg ⤷  Try a Trial PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
1556389 SPC/GB16/002 United Kingdom ⤷  Try a Trial PRODUCT NAME: CEFTOLOZANE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR A SULFURIC ACID SALT.; REGISTERED: UK EU/1/15/1032 20150922
1345920 SPC/GB14/018 United Kingdom ⤷  Try a Trial PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220
1556389 2015/074 Ireland ⤷  Try a Trial PRODUCT NAME: CEFTOLOZANE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR A SULFURIC ACID SALT; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.